Health Care · Pharmaceutical Preparations

ACAD ACADIA PHARMACEUTICALS INC SEC Filings & Insider Trading Activity 2026

company
CIK 1070494127 filings
Russell 2000

ACAD at a glance

ACADIA PHARMACEUTICALS INC (ACAD, SEC CIK 1070494) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as October 30, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), ACADIA PHARMACEUTICALS INC (ACAD) reported revenue of $1.1 billion (up 11.9% from FY2024) and net income of $391.0 million. Diluted EPS was $2.30.
  • As of September 30, 2026, 31 institutional investment managers tracked by SignalX reported holding ACADIA PHARMACEUTICALS INC (ACAD) shares worth $1.4 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Schneyer Mark C. on October 30, 2026 of 3,321 shares at $20.88 per share.
  • In the last 90 days, ACAD insiders reported 0 open-market purchases ($0) and 1 open-market sale ($69K) on Form 4, a net sale of $69K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$1.1B
+11.9% vs prior year
Insiders · 90 days
0 buys · 1 sell
Net −$69K
13F holders
31 funds
$1.4B · −3 vs prior quarter
Latest 8-K
Nov 4, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Risk Factors

  • Cybersecurity incident escalation to audit committee requiring coordination among CIDO, Chief Legal Officer, and Senior VP of Finance
  • New CIDO hired August 2025 tasked with integrating cybersecurity risk into overall risk strategy
  • Senior Director of Info Security with decade-long company tenure leads cybersecurity risk management processes
  • Incident response includes cross-functional senior management team and security operations integration
  • Governance oversight involves regular audit committee reviews of cybersecurity threats and mitigation efforts

Management Discussion & Analysis

  • Revenue $1,071.5M in 2025 vs $957.8M in 2024, driven by NUPLAZID and DAYBUE sales, up $113.7M YoY
  • Operating loss driven by R&D expenses $328.8M in 2025 vs $303.2M in 2024; gross-to-net adjustments reduced net sales by $20.1M from Medicare rebate revision
  • Best performing: DAYBUE, contributing significantly with expanded approvals; worst: ACP-101 discontinued post Phase 3 failure
  • Cash inflows included $146.5M Rare Pediatric Disease PRV sale in 2024; capital outlays include $12M upfront and milestone payments in R&D for 2025
  • Forward outlook notes substantial R&D investments continuing for remlifanserin and early-stage candidates; risks include regulatory milestone uncertainties and potential clinical trial delays

Business Overview

  • Core business: biopharmaceutical focus on neurological and rare diseases with $1.07B net sales from NUPLAZID and DAYBUE in 2025, up from $958M in 2024
  • New product launch: DAYBUE STIX powder formulation introduced in Q1 2026 for Rett syndrome, offering dosing flexibility and improved patient experience
  • Strategic shift: expanding global footprint with EMA marketing authorization application and re-examination request after negative CHMP vote for trofinetide in Rett syndrome
  • Quantitative highlight: initiated three Phase 2 studies in 2025-2026; remlifanserin for ADP and LBDP, ACP-211 for MDD, and planned ACP-711 Phase 2 start for essential tremor
  • Noteworthy fact: discontinued development of ACP-101 after Phase 3 failure in Prader-Willi syndrome, refocusing resources on neurological and rare disease pipeline

AI summary of the ACAD 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Newly added tariff risk triggered by U.S. pharmaceutical trade investigations, potentially raising costs and delaying supply-chain adjustments
  • Most materially updated supply risk: DAYBUE API production requires approximately twelve months, increasing vulnerability to disruptions
  • Regulatory risk: EU HTA Regulation entered application January 12, 2025, creating uncertain evidence requirements and reimbursement timing
  • Clinical risk: RADIANT Phase 2 narrowly missed its primary endpoint, prompting removal of the 30 mg remlifanserin dosage arm
  • Liquidity risk: cash, cash equivalents, investment securities and anticipated product sales expected to fund operations through and beyond the next 12 months

Management Discussion & Analysis

  • Quarterly revenue $342.3M, up $63.7M YoY from $278.6M
  • DAYBUE products best performer, $140.1M vs $101.1M, up $39.0M YoY
  • Gross margin approximately 90% vs 92% YoY, pressured by higher DAYBUE sales mix
  • Cash and investments $976.4M vs $819.7M at December 31, 2025, operating cash flow $146.3M
  • Outlook: cash sufficient through and beyond next 12 months, $35.0M Neuren milestone due after first EU DAYBU sale

AI summary of the ACAD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release covers financial results for the nine months ended September 30, 2026
  • Exhibit 99.1 contains the detailed results and management commentary

Item EX-99.1: Item EX-99.1

  • Q3 revenue $342.3M, up 23% YoY, with DAYBUE $140.1M, up 39%, and NUPLAZID $202.2M, up 14% GAAP
  • 2026 DAYBUE guidance raised to $505M-$520M, signaling stronger commercial uptake and improved visibility for the growth franchise
Filed Oct 23, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Elizabeth H.Z. Thompson retires October 23, 2026 as Executive Vice President and Head of Research and Development
  • Limited consulting arrangement through December 31, 2026, preserving short-term R&D transition support
Filed Sep 24, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Phase 2 primary endpoint narrowly missed: SAPS-H+D change -12.6 vs -10.4 placebo, p=0.0603
  • Key secondary CGI-S-ADP favored 60 mg: change -1.3 vs -0.9 placebo, nominal p=0.0077

Item 8.01: Other Events

  • 60 mg remlifanserin improved SAPS-H+D versus placebo at week 6, but primary endpoint missed nominal significance: p=0.0603
  • CGI-S-ADP favored 60 mg, effect size 0.37 with nominal p=0.0077

Item 7.01: Regulation FD Disclosure

  • Phase 2 topline results from RADIANT support Phase 3 planning for remlifanserin in Alzheimer’s disease psychosis
  • Target indication, hallucinations and delusions associated with Alzheimer’s disease psychosis

AI summaries of ACAD 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for ACAD

Don't miss the next ACAD filing

  • Alerts as it files. A push when ACAD files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut ACAD, by share count.
  • Ask anything. An AI agent that reads every ACAD filing and answers with sources.

ACAD alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Schneyer Mark C.SellOct 30, 2026$20.88
Schneyer Mark C.AOct 15, 2026-
Schneyer Mark C.MAug 6, 2026-
Schneyer Mark C.SellAug 6, 2026$29.00
Schneyer Mark C.SellAug 6, 2026$29.34
Schneyer Mark C.MAug 6, 2026$17.84
Schneyer Mark C.MAug 5, 2026-
Schneyer Mark C.MAug 5, 2026$17.84

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$957.8M$1.1B
Operating Income-$73.4M$230.8M$104.8M
Net Income-$226.5M$391.0M
Op. Margin-24.1%9.8%
Net Margin-23.6%36.5%
Balance Sheet
Total Assets$749.0M$1.2B$1.6B
Equity$431.8M$732.8M$1.2B
ROE-30.9%31.9%
Per Share
EPS-$1.36$2.30
Cash Flow
Operating CF-$157.7M$109.8M
CapEx$50K$523K$4.7M

Source: XBRL data in ACADIA PHARMACEUTICALS INC (ACAD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate ACAD share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
ACAD shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202631$1.43B
Q2 202634$1.72B
Q1 202634$1.41B
Q4 202530$1.70B
Q3 202531$1.41B
Q2 202530$1.45B
Q1 202528$707.8M
Q4 202423$570.4M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 241 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

ACAD filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 5, 2026Analysis
8-KNov 4, 2026Analysis-
4Oct 30, 2026--
8-KOct 23, 2026Analysis-
8-KSep 24, 2026Analysis-
8-KSep 11, 2026Analysis-
SC 13GAug 7, 2026-
4Aug 7, 2026--
10-QAug 5, 2026Analysis
8-KAug 4, 2026Analysis-
4Jul 31, 2026--
4Jun 29, 2026--
4Jun 2, 2026-
4Jun 1, 2026-
4Jun 1, 2026-
4Jun 1, 2026-
4Jun 1, 2026-
4Jun 1, 2026-
4Jun 1, 2026-
8-KMay 29, 2026Analysis
4May 27, 2026-
10-QMay 7, 2026Analysis
8-KMay 6, 2026Analysis
4May 5, 2026--
4May 5, 2026--

Related Health Care companies

All Health Care →

ACAD SEC filings: frequently asked questions

Are ACAD insiders buying or selling?

In the last 90 days, ACADIA PHARMACEUTICALS INC (ACAD) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $69,342 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold ACAD stock?

As of September 30, 2026, the largest ACADIA PHARMACEUTICALS INC (ACAD) holders among the 13F filers tracked by SignalX were BlackRock ($462.4 million), Vanguard Portfolio Management LLC ($190.6 million), State Street Corp ($154.2 million), Vanguard Capital Management LLC ($116.7 million), Goldman Sachs Group ($93.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was ACAD's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), ACADIA PHARMACEUTICALS INC (ACAD) reported revenue of $1.1 billion (up 11.9% from FY2024) and net income of $391.0 million. Diluted EPS was $2.30. The figures come from the XBRL data in the 10-K.

What are the main risks in ACAD's latest 10-K?

In the 10-K filed February 26, 2026, ACADIA PHARMACEUTICALS INC (ACAD) flagged: Cybersecurity incident escalation to audit committee requiring coordination among CIDO, Chief Legal Officer, and Senior VP of Finance. New CIDO hired August 2025 tasked with integrating cybersecurity risk into overall risk strategy. (AI summary of the Risk Factors section.)

What did ACAD report in its latest 8-K?

ACADIA PHARMACEUTICALS INC (ACAD) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release covers financial results for the nine months ended September 30, 2026.

What are the latest ACAD SEC filings?

ACADIA PHARMACEUTICALS INC (ACAD) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on October 30, 2026.

What is ACAD's SEC CIK number?

ACADIA PHARMACEUTICALS INC (ACAD)'s SEC Central Index Key (CIK) is 1070494. EDGAR lists every ACAD filing under that number.

Ask anything about ACAD

The research agent reads ACAD's filings, financials, insider trades and 13F holders, then answers with sources.